Victory Capital Management Inc. raised its position in shares of Johnson & Johnson (NYSE:JNJ) by 40.1% in the third quarter, HoldingsChannel.com reports. The firm owned 222,470 shares of the company’s stock after acquiring an additional 63,633 shares during the period. Victory Capital Management Inc.’s holdings in Johnson & Johnson were worth $28,924,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors have also recently bought and sold shares of JNJ. BlackRock Inc. boosted its stake in Johnson & Johnson by 2.6% during the 2nd quarter. BlackRock Inc. now owns 174,073,764 shares of the company’s stock valued at $23,028,219,000 after purchasing an additional 4,332,612 shares during the period. Janus Henderson Group PLC boosted its stake in Johnson & Johnson by 717.9% during the 2nd quarter. Janus Henderson Group PLC now owns 3,748,008 shares of the company’s stock valued at $495,837,000 after purchasing an additional 3,289,763 shares during the period. Vanguard Group Inc. lifted its stake in shares of Johnson & Johnson by 1.5% in the 2nd quarter. Vanguard Group Inc. now owns 200,450,985 shares of the company’s stock worth $26,517,661,000 after acquiring an additional 3,023,110 shares during the period. Parametric Portfolio Associates LLC lifted its stake in shares of Johnson & Johnson by 47.9% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 7,970,670 shares of the company’s stock worth $1,054,433,000 after acquiring an additional 2,581,562 shares during the period. Finally, Harbour Capital Advisors LLC lifted its stake in shares of Johnson & Johnson by 13,327.8% in the 2nd quarter. Harbour Capital Advisors LLC now owns 2,501,472 shares of the company’s stock worth $18,909,000 after acquiring an additional 2,482,843 shares during the period. 65.70% of the stock is owned by hedge funds and other institutional investors.
A number of brokerages have recently weighed in on JNJ. Vetr raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $150.89 price target for the company in a research note on Thursday. Wells Fargo & Co reaffirmed an “outperform” rating and issued a $160.00 price target (up from $155.00) on shares of Johnson & Johnson in a research note on Friday. Royal Bank of Canada reaffirmed a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, January 9th. JPMorgan Chase & Co. lowered shares of Johnson & Johnson from an “overweight” rating to a “neutral” rating in a research note on Tuesday, January 2nd. Finally, Citigroup began coverage on shares of Johnson & Johnson in a research note on Monday, September 25th. They issued a “neutral” rating and a $140.00 price target for the company. Four equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and eleven have assigned a buy rating to the company. Johnson & Johnson presently has a consensus rating of “Hold” and an average target price of $145.94.
Shares of Johnson & Johnson (NYSE JNJ) opened at $145.76 on Friday. Johnson & Johnson has a one year low of $110.76 and a one year high of $146.42. The company has a market cap of $391,590.00, a P/E ratio of 25.31, a P/E/G ratio of 2.75 and a beta of 0.80. The company has a current ratio of 1.32, a quick ratio of 1.02 and a debt-to-equity ratio of 0.36.
Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, October 17th. The company reported $1.90 EPS for the quarter, beating the consensus estimate of $1.80 by $0.10. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The business had revenue of $19.65 billion during the quarter, compared to analyst estimates of $19.29 billion. During the same period in the prior year, the business earned $1.68 earnings per share. The business’s quarterly revenue was up 10.3% on a year-over-year basis. equities analysts predict that Johnson & Johnson will post 7.28 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 13th. Investors of record on Tuesday, February 27th will be paid a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a yield of 2.31%. The ex-dividend date is Monday, February 26th. Johnson & Johnson’s dividend payout ratio is presently 58.33%.
ILLEGAL ACTIVITY WARNING: This article was first reported by Stock Observer and is owned by of Stock Observer. If you are accessing this article on another publication, it was illegally copied and republished in violation of international copyright and trademark law. The original version of this article can be accessed at https://www.thestockobserver.com/2018/01/14/victory-capital-management-inc-has-28-92-million-holdings-in-johnson-johnson-jnj.html.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.